According to a recent study published in Archives of gynecology and obstetrics, Dienogest, a progestogen-only hormone preparation can effectively treat the endometriosis-related pain.

Endometriosis is counted among the most prevalent disease affecting almost 10% of women worldwide in their childbearing age. Pharmacological treatments for endometriosis aim to suppress ovarian function. One of such drugs is Dienogest, that works by suppressing estradiol production and by preventing endometrium growth. However, very little evidence is present regarding its efficacy. Therefore, a single-center, observational and cohort study was conducted to evaluate the efficacy of Dienogest.

A total of 132 women were included in the study. Out of which only 21 selected for further analysis and other got excluded due to adverse effects. The women who diagnosed with endometriosis for more than 24 months and with endometriosis-associated pelvic pain were involved in the study. The score of the pain among these females was at least up to 40 mm on a 100-mm visual analogue scale (VAS) at the beginning of the treatment. These patients were administered with 2 mg  Dienogest once daily for maximum 30 days at the time of study entry, from September 2013 to September 2014. These women came back for their clinical pain evaluation after 1 (V1), 3 (V2), and 12 (V3) months.

At the baseline, the VAS score for pelvic pain was 8.9. Along with pain and other symptoms such as dyspareunia and dyschezia were also measured through VAS score, which was 6.7 and 5.7 respectively, at the baseline. After 12-month treatment, a significant decrease was seen in the VAS score of pain and other symptoms. The VAS score measured was 0.9, 1.4 and 0.2 for pain, dyspareunia and dyschezia, respectively.

The whole analysis concluded that Dienogest (2 mg, once daily) was well adapted and effective in the treatment of endometriosis-related pain.